- About
- PsychU For You
- Topics
- Events
- Content
Clinical Perspectives on the Impact of Agitation in Alzheimer’s Dementia Among the Hispanic Community
Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Clinical Perspectives on the Impact of Agitation in Alzheimer’s Dementia Among the Hispanic Community
Latinos/Hispanics represent the fastest-growing population in the United States yet, they face significant health disparities in Alzheimer’s Dementia (AD) diagnosis and care.1 Join us for an enlightening discussion moderated by John Awad, MD, alongside esteemed speakers Freddi Segal-Gidan, PA, PhD (Keck School of Medicine of University of Southern California) and Daniel Jimenez, PhD (University of Miami), as they share their clinical perspectives on the impact of AD among the Hispanic population, analyze the risk factors and clinical outcomes challenges that the patients and caregivers may face, discuss the profound effect of agitation in Alzheimer’s Dementia (AAD) within this population and explore the roles of the medical community in addressing symptoms of agitation.
References:
- Alzheimer’s Disease in the Latino Community: Intersection of Genetics and Social Determinants of Health. Irving E. Vega et al. J Alzheimers Dis. 2017; 58(4): 979–992.
Freddi Segal-Gidan, PA, PhD
Director of the USC-Rancho California Alzheimer's Disease Center – LA County Department of Health. Associate Professor of Clinical Neurology and Family Medicine – Keck School of Medicine, University of South California
Daniel Jimenez, PhD
Associate Professor in the Department of Psychiatry and Behavioral Sciences – Univ. of Miami Miller School of Medicine. President-Elect of the American Society of Hispanic Psychiatry
John Awad, MD (OPDC)
Senior Medical Science Liaison
Freddi Segal-Gidan, PA PhD is a volunteer and has declined payment for this activity.
Daniel Jimenez, PhD is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc.
John Awad, MD is a paid employee of Otsuka Pharmaceutical Development & Commercialization, Inc.
Disclaimer: PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI). Specific PsychU programs may be supported by OPDC, OAPI and other committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsor or the sponsors of the specific PsychU program in which such opinions are expressed. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC and OAPI.
June 2024 US.CORP.X.24.00182Related Events
Registration
- PsychU For You
